Trial Outcomes & Findings for Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC (NCT NCT03989115)
NCT ID: NCT03989115
Last Updated: 2023-06-26
Results Overview
An adverse event (AE) was defined as any untoward medical occurrence in a participant, temporally associated with the use of a pharmaceutical / an investigational product, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product(s) was also an AE. All AEs and SAEs will be collected from the start of intervention until the safety visit or EOT visit, whichever is later. The number of safety-evaluable participants who experienced at least one treatment-emergent AE was reported per protocol.
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
113 participants
Primary outcome timeframe
AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Results posted on
2023-06-26
Participant Flow
Participant milestones
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
8
|
6
|
12
|
7
|
65
|
7
|
4
|
4
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
8
|
6
|
12
|
7
|
65
|
7
|
4
|
4
|
Reasons for withdrawal
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
|---|---|---|---|---|---|---|---|---|
|
Overall Study
Withdrawal by Subject
|
2
|
1
|
3
|
0
|
17
|
1
|
0
|
0
|
|
Overall Study
Sponsor decision to terminate the study
|
1
|
1
|
0
|
1
|
11
|
0
|
2
|
1
|
|
Overall Study
Lost to Follow-up
|
2
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
Overall Study
Death
|
2
|
2
|
9
|
6
|
31
|
6
|
2
|
3
|
|
Overall Study
Other
|
1
|
2
|
0
|
0
|
5
|
0
|
0
|
0
|
Baseline Characteristics
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Baseline characteristics by cohort
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=8 Participants
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21 days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40 mg QD 21 days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=12 Participants
Participants who received intermittent dose of RMC-4630 140mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21 days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
n=7 Participants
Participants who received intermittent dose of RMC-4630 140mg on D1 and D2 of a 28-day cycle and Cobimetinib 20 mg QD 21 days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
n=65 Participants
Participants who received intermittent dose of RMC-4630 140mg on D1 and D2 of a 28-day cycle and Cobimetinib 40 mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg (D1D2)
n=7 Participants
Participants who received intermittent dose of RMC-4630 140mg on D1 and D2 of a 28-day cycle and Cobimetinib 60 mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg QD
n=4 Participants
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and Osimertinib 80 mg QD.
|
IIntermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg QD
n=4 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Osimertinib 80 mg QD.
|
Total
n=113 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
0 Participants
n=193 Participants
|
0 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
8 Participants
n=39 Participants
|
4 Participants
n=41 Participants
|
6 Participants
n=35 Participants
|
7 Participants
n=31 Participants
|
50 Participants
n=146 Participants
|
6 Participants
n=19 Participants
|
2 Participants
n=147 Participants
|
2 Participants
n=193 Participants
|
85 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=39 Participants
|
2 Participants
n=41 Participants
|
6 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
15 Participants
n=146 Participants
|
1 Participants
n=19 Participants
|
2 Participants
n=147 Participants
|
2 Participants
n=193 Participants
|
28 Participants
|
|
Sex: Female, Male
Female
|
5 Participants
n=39 Participants
|
4 Participants
n=41 Participants
|
5 Participants
n=35 Participants
|
2 Participants
n=31 Participants
|
34 Participants
n=146 Participants
|
4 Participants
n=19 Participants
|
2 Participants
n=147 Participants
|
2 Participants
n=193 Participants
|
58 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=39 Participants
|
2 Participants
n=41 Participants
|
7 Participants
n=35 Participants
|
5 Participants
n=31 Participants
|
31 Participants
n=146 Participants
|
3 Participants
n=19 Participants
|
2 Participants
n=147 Participants
|
2 Participants
n=193 Participants
|
55 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
0 Participants
n=193 Participants
|
1 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
5 Participants
n=35 Participants
|
1 Participants
n=31 Participants
|
8 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
4 Participants
n=147 Participants
|
2 Participants
n=193 Participants
|
21 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
4 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
1 Participants
n=193 Participants
|
5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=39 Participants
|
1 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
0 Participants
n=193 Participants
|
1 Participants
|
|
Race (NIH/OMB)
White
|
7 Participants
n=39 Participants
|
5 Participants
n=41 Participants
|
7 Participants
n=35 Participants
|
6 Participants
n=31 Participants
|
45 Participants
n=146 Participants
|
5 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
1 Participants
n=193 Participants
|
76 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
7 Participants
n=146 Participants
|
2 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
0 Participants
n=193 Participants
|
9 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=147 Participants
|
0 Participants
n=193 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.Population: All safety-evaluable participants who experienced at least one treatment-emergent AE.
An adverse event (AE) was defined as any untoward medical occurrence in a participant, temporally associated with the use of a pharmaceutical / an investigational product, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product(s) was also an AE. All AEs and SAEs will be collected from the start of intervention until the safety visit or EOT visit, whichever is later. The number of safety-evaluable participants who experienced at least one treatment-emergent AE was reported per protocol.
Outcome measures
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=8 Participants
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=12 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
n=7 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
n=65 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
n=7 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Adverse Events (AEs).
|
8 Participants
|
6 Participants
|
12 Participants
|
7 Participants
|
64 Participants
|
7 Participants
|
4 Participants
|
4 Participants
|
PRIMARY outcome
Timeframe: Cycle 1: Study Day 1 - Study Day 28 (28 days)Population: DLT-evaluable population was defined as the following: All treated participants in the dose escalation phase who completed the DLT period and received at least 75% of planned dose of RMC-4630 and cobimetinib or RMC-4630 and Osimertinib (ie, not have missed ≥3 doses of RMC-4630 and cobimetinib on the D1D2 intermittent schedule or ≥6 doses of cobimetinib on the 21 on/7 off schedule, or ≥8 doses for reasons other than toxicity) within the DLT observation period (i.e Cycle 1)
Any toxicities occurring during the DLT observation period (cycle 1) that were considered R/T study treatment, including GR4 AEs; GR3 febrile neutropenia or hemorrhage; GR3 thrombocytopenia with clinically significant bleeding; GR ≥2 pneumonitis; GR3 hypertension or rash which does not improve or remains uncontrolled for \>5 or more days despite maximal supportive care; GR3 non hematologic AEs that remain uncontrolled for \>72 hours despite maximal supportive care; Concurrent elevation of AST or ALT \>3 × ULN \& total bilirubin \>2 × ULN or international normalized ratio (INR) \>1.5 in the absence of cholestasis and other causes; Grade 3 QTcF prolongation based on a triplicate ECG; Ejection fraction \<50% with an absolute decrease of \>10% from baseline; Retinal vein occlusion any grade; 50% or less dose intensity of RMC4630 and/or cobimetnib or osimertinib due to study drug related toxicity. Refer to protocol for further details.
Outcome measures
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=9 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
n=5 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
n=6 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Dose Limiting Toxicities (DLTs)
|
1 Participants
|
0 Participants
|
3 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: 0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15Peak plasma concentration of RMC-4630 and cobimetinib or RMC-4630 and osimertinib
Outcome measures
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=8 Participants
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=12 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
n=7 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
n=65 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
n=7 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
|---|---|---|---|---|---|---|---|---|
|
Cmax
C1D15
|
207 ng/mL
Geometric Coefficient of Variation 90
|
266 ng/mL
Geometric Coefficient of Variation 64
|
465 ng/mL
Geometric Coefficient of Variation 37
|
504 ng/mL
Geometric Coefficient of Variation 71
|
395 ng/mL
Geometric Coefficient of Variation 56
|
469 ng/mL
Geometric Coefficient of Variation 20
|
286 ng/mL
Geometric Coefficient of Variation 38
|
408 ng/mL
Geometric Coefficient of Variation 3
|
|
Cmax
C1D1
|
214 ng/mL
Geometric Coefficient of Variation 45
|
248 ng/mL
Geometric Coefficient of Variation 38
|
469 ng/mL
Geometric Coefficient of Variation 42
|
430 ng/mL
Geometric Coefficient of Variation 61
|
354 ng/mL
Geometric Coefficient of Variation 52
|
449 ng/mL
Geometric Coefficient of Variation 27
|
242 ng/mL
Geometric Coefficient of Variation 57
|
449 ng/mL
Geometric Coefficient of Variation 25
|
SECONDARY outcome
Timeframe: 0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15Time to achieve peak plasma concentration of RMC-4630 and cobimetinib or RMC-4630 and osimertinib
Outcome measures
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=8 Participants
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=12 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
n=7 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
n=65 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
n=7 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
|---|---|---|---|---|---|---|---|---|
|
Tmax
C1D1
|
2.94 h
Interval 1.0 to 4.13
|
2.00 h
Interval 1.0 to 2.03
|
1.99 h
Interval 0.9 to 7.5
|
1.02 h
Interval 0.98 to 2.0
|
2.00 h
Interval 0.42 to 8.0
|
1.92 h
Interval 0.92 to 3.97
|
2.03 h
Interval 0.98 to 7.55
|
2.95 h
Interval 1.07 to 4.1
|
|
Tmax
C1D15
|
2.04 h
Interval 1.0 to 4.07
|
2.08 h
Interval 0.97 to 4.99
|
3.04 h
Interval 1.87 to 7.77
|
1.08 h
Interval 1.0 to 2.12
|
2.00 h
Interval 0.57 to 23.7
|
1.96 h
Interval 0.97 to 2.07
|
1.98 h
Interval 1.88 to 2.0
|
4.07 h
Interval 4.05 to 4.08
|
SECONDARY outcome
Timeframe: 0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15Area under the plasma concentration time curve of RMC-4630 and cobimetinib or RMC-4630 and osimertinib
Outcome measures
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=8 Participants
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=12 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
n=7 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
n=65 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
n=7 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
|---|---|---|---|---|---|---|---|---|
|
Area Under the Curve (AUC)
C1D1
|
2570 ng/mL x h
Geometric Coefficient of Variation 34
|
2580 ng/mL x h
Geometric Coefficient of Variation 30
|
5510 ng/mL x h
Geometric Coefficient of Variation 38
|
4610 ng/mL x h
Geometric Coefficient of Variation 39
|
4700 ng/mL x h
Geometric Coefficient of Variation 38
|
4720 ng/mL x h
Geometric Coefficient of Variation 26
|
3360 ng/mL x h
Geometric Coefficient of Variation 28
|
5920 ng/mL x h
Geometric Coefficient of Variation 15
|
|
Area Under the Curve (AUC)
C1D15
|
3220 ng/mL x h
Geometric Coefficient of Variation 91
|
3360 ng/mL x h
Geometric Coefficient of Variation 44
|
6370 ng/mL x h
Geometric Coefficient of Variation 37
|
5580 ng/mL x h
Geometric Coefficient of Variation 45
|
5460 ng/mL x h
Geometric Coefficient of Variation 45
|
5600 ng/mL x h
Geometric Coefficient of Variation 18
|
4230 ng/mL x h
Geometric Coefficient of Variation 35
|
5500 ng/mL x h
Geometric Coefficient of Variation 26
|
SECONDARY outcome
Timeframe: 0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15AUC ratio (C1D15 versus C1D1) of RMC-4630 and cobimetinib or RMC-4630 and osimertinib
Outcome measures
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=8 Participants
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=12 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
n=7 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
n=65 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
n=7 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
|---|---|---|---|---|---|---|---|---|
|
Accumulation Ratio
|
1.36 ratio
Geometric Coefficient of Variation 56
|
1.22 ratio
Geometric Coefficient of Variation 24
|
1.24 ratio
Geometric Coefficient of Variation 16
|
1.20 ratio
Geometric Coefficient of Variation 28
|
1.19 ratio
Geometric Coefficient of Variation 41
|
1.20 ratio
Geometric Coefficient of Variation 41
|
1.12 ratio
Geometric Coefficient of Variation 20
|
0.841 ratio
Geometric Coefficient of Variation 41
|
SECONDARY outcome
Timeframe: Response assessment occurs from the start of intervention until the date of documented disease progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first.Population: There were insufficient number of participants with events to calculate.
Duration of response of RMC-4630 and cobimetinib or RMC-4630 and osimertinib per RECIST v1.1
Outcome measures
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
n=1 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
|---|---|---|---|---|---|---|---|---|
|
Duration of Response (DOR)
|
—
|
—
|
—
|
—
|
NA day(s)
insufficient number of participants with events to calculate
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 0, 0.5, 1, 2, 4, 8, 24 hours post-dose on Cycle1 Day 1 and Cycle 1 Day 15Elimination half-life of RMC-4630 and cobimetinib or RMC-4630 and osimertinib
Outcome measures
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=8 Participants
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=12 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
n=7 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
n=65 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
n=7 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
n=4 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
|---|---|---|---|---|---|---|---|---|
|
t1/2
C1D1
|
15.7 h
Interval 12.3 to 20.2
|
16.1 h
Interval 15.2 to 20.9
|
15.1 h
Interval 11.7 to 20.6
|
16.2 h
Interval 15.1 to 35.7
|
17.0 h
Interval 10.8 to 26.2
|
16.9 h
Interval 14.9 to 20.1
|
20.1 h
Interval 14.0 to 26.2
|
16.6 h
Interval 16.6 to 16.6
|
|
t1/2
C1D15
|
20.8 h
Interval 15.0 to 31.2
|
24.5 h
Interval 19.8 to 29.2
|
15.7 h
Interval 14.9 to 17.3
|
22.2 h
Interval 16.5 to 91.7
|
14.4 h
Interval 5.18 to 18.2
|
18.4 h
Interval 11.3 to 24.8
|
24.6 h
Interval 15.2 to 25.2
|
NA h
Insufficient timepoints to calculate this data.
|
SECONDARY outcome
Timeframe: Response assessment occurs from the start of intervention until the date of documented disease progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first.ORR is defined as the proportion of participants who achieve a CR or PR per RECIST v1.1. ORR and the corresponding 95% two-sided confidence interval were derived.
Outcome measures
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=8 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
n=6 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
n=55 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
n=6 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
n=3 Participants
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
n=3 Participants
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.
|
|---|---|---|---|---|---|---|---|---|
|
Overall Response Rate (ORR)
|
0 % of participants
Interval 0.0 to 45.9
|
0 % of participants
Interval 0.0 to 45.9
|
0 % of participants
Interval 0.0 to 36.9
|
0 % of participants
Interval 0.0 to 45.9
|
1.82 % of participants
Interval 0.0 to 9.7
|
0 % of participants
Interval 0.0 to 45.9
|
0 % of participants
Interval 0.0 to 7.1
|
0 % of participants
Interval 0.0 to 7.1
|
Adverse Events
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
Serious events: 2 serious events
Other events: 8 other events
Deaths: 2 deaths
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
Serious events: 4 serious events
Other events: 6 other events
Deaths: 2 deaths
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
Serious events: 3 serious events
Other events: 12 other events
Deaths: 9 deaths
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
Serious events: 3 serious events
Other events: 7 other events
Deaths: 6 deaths
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
Serious events: 29 serious events
Other events: 64 other events
Deaths: 31 deaths
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
Serious events: 3 serious events
Other events: 7 other events
Deaths: 6 deaths
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
Serious events: 1 serious events
Other events: 4 other events
Deaths: 2 deaths
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
Serious events: 1 serious events
Other events: 4 other events
Deaths: 3 deaths
Serious adverse events
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=8 participants at risk
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
n=6 participants at risk
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=12 participants at risk
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
n=7 participants at risk
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
n=65 participants at risk
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
n=7 participants at risk
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
n=4 participants at risk
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
n=4 participants at risk
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle
|
|---|---|---|---|---|---|---|---|---|
|
Respiratory, thoracic and mediastinal disorders
haemoptysis
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
ileus paralytic
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
intestinal obstruction
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
gastrointestinal hemorrhage
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
large intestinal obstruction
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
small intestinal obstruction
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
vomiting
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
abdominal pain
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
diarrhoea
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
upper gastrointestinal haemorrhage
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
pneumonia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
4.6%
3/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
sepsis
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
COVID-19 pneumonia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
pneumonia legionella
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
pneumonitis
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
malignant pleural effusion
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Psychiatric disorders
confusional state
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
nausea
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
oesophagitis
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
proctalgia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
rectal haemorrhage
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
hypoxia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
pleural effusion
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
pulmonary embolism
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
dyspnoea
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
dehydration
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
hyperkalaemia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
hypoglycaemia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
hyponatraemia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
non-cardiac chest pain
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
pyrexia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Blood and lymphatic system disorders
anaemia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Blood and lymphatic system disorders
thrombocytopenia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Cardiac disorders
myocardial infarction
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Cardiac disorders
acute myocardial infarction
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Cardiac disorders
cardiac failure acute
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Nervous system disorders
cognitive disorder
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Nervous system disorders
headache
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Nervous system disorders
lethargy
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Vascular disorders
deep vein thrombosis
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Vascular disorders
hypotension
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Vascular disorders
jugular vein thrombosis
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
alanine aminotransferase increased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
aspartate aminotransferase increased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
platelet count decreased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Musculoskeletal and connective tissue disorders
pathological fracture
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
Other adverse events
| Measure |
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=8 participants at risk
Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle
|
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
n=6 participants at risk
Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle
|
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
n=12 participants at risk
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
n=7 participants at risk
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
n=65 participants at risk
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle
|
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
n=7 participants at risk
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle
|
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)
n=4 participants at risk
Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle
|
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
n=4 participants at risk
Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle
|
|---|---|---|---|---|---|---|---|---|
|
General disorders
oedema peripheral
|
25.0%
2/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
33.3%
2/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
33.3%
4/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
33.8%
22/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Injury, poisoning and procedural complications
fall
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Reproductive system and breast disorders
erectile dysfunction
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Reproductive system and breast disorders
anisomastia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Reproductive system and breast disorders
pelvic pain
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
fatigue
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
50.0%
3/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
3/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
42.9%
3/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
35.4%
23/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
100.0%
4/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
diarrhoea
|
75.0%
6/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
100.0%
6/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
91.7%
11/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
85.7%
6/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
81.5%
53/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
100.0%
7/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
75.0%
3/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
100.0%
4/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
nausea
|
25.0%
2/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
33.3%
2/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
3/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
36.9%
24/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
42.9%
3/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
constipation
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
29.2%
19/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
vomiting
|
25.0%
2/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
33.3%
2/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
20.0%
13/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
42.9%
3/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
abdominal pain
|
25.0%
2/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
21.5%
14/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
abdominal distention
|
25.0%
2/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
50.0%
3/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
13.8%
9/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
dry mouth
|
25.0%
2/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
13.8%
9/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
ascites
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
33.3%
2/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
6.2%
4/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
pyrexia
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
3/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
20.0%
13/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
dyspnoea
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
50.0%
3/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
41.7%
5/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
32.3%
21/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
50.0%
2/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
cough
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
3/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
13.8%
9/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
pleural effusion
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
3/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
10.8%
7/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
50.0%
2/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
aspartate aminotransferase increased
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
33.3%
2/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
57.1%
4/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.9%
11/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
platelet count decreased
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
15.4%
10/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
blood creatine phosphokinase increased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
50.0%
3/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
9.2%
6/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
lymphocyte count decreased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
71.4%
5/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
decreased appetite
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
33.3%
2/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
21.5%
14/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
75.0%
3/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
hypoalbuminaemia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
33.3%
2/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.9%
11/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
hypomagnesaemia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
50.0%
3/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
7.7%
5/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
dehydration
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
10.8%
7/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
50.0%
2/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
hyponatraemia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
66.7%
4/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
7.7%
5/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Blood and lymphatic system disorders
anaemia
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
50.0%
3/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
41.7%
5/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
57.1%
4/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
35.4%
23/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Blood and lymphatic system disorders
thrombocytopenia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
33.3%
2/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
3/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
10.8%
7/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Eye disorders
vision blurred
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
15.4%
10/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Skin and subcutaneous tissue disorders
rash maculo-papular
|
25.0%
2/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
6.2%
4/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
50.0%
2/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Skin and subcutaneous tissue disorders
dry skin
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
6.2%
4/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
50.0%
2/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Nervous system disorders
dizziness
|
25.0%
2/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.9%
11/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
50.0%
2/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
gait disturbance
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Skin and subcutaneous tissue disorders
decubitus ulcer
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Injury, poisoning and procedural complications
foot fracture
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Injury, poisoning and procedural complications
skin laceration
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
reticulocyte count increased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
nail infection
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Reproductive system and breast disorders
scrotal haemorrhage
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
non-cardiac chest pain
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
10.8%
7/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
asthenia
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
4.6%
3/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
chills
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
generalised oedema
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
face oedema
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
6.2%
4/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
peripheral swelling
|
25.0%
2/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
localised oedema
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
oedema
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
hypoxia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
15.4%
10/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
nasal congestion
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
dyspnoea exertional
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
oropharyngeal pain
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
pneumonitis
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
respiratory failure
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
blood alkaline phosphatase increased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
33.3%
2/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
9.2%
6/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
weight increased
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
10.8%
7/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
blood creatinine increased
|
25.0%
2/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
9.2%
6/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
gamma-glutamyltranferase increased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
7.7%
5/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
alanine aminotransferase increased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
7.7%
5/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
blood bilirubin increased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
6.2%
4/65 • Number of events 4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
white blood cell count decreased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
hypokalaemia
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
18.5%
12/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
weight decreased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
hypophosphataemia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
42.9%
3/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Eye disorders
dry eye
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
4.6%
3/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Skin and subcutaneous tissue disorders
dermatitis acneiform
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
7.7%
5/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Skin and subcutaneous tissue disorders
rash
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
6.2%
4/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Skin and subcutaneous tissue disorders
skin hyperpigmentation
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Nervous system disorders
headache
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
9.2%
6/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Nervous system disorders
syncope
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
urinary tract infection
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
6.2%
4/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
pneumonia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Renal and urinary disorders
proteinuria
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
9.2%
6/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Renal and urinary disorders
haematuria
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Renal and urinary disorders
nephrolithiasis
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Cardiac disorders
sinus tachycardia
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
6.2%
4/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Vascular disorders
hypotension
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
2/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
9.2%
6/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Vascular disorders
hypertension
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
10.8%
7/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
75.0%
3/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Blood and lymphatic system disorders
leukopenia
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Eye disorders
periorbital oedema
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Blood and lymphatic system disorders
neutropenia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
dyspepsia
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
10.8%
7/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
abdominal pain upper
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
4.6%
3/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
flatulence
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
4.6%
3/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
gastrooesophageal reflux disease
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
4.6%
3/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
rectal haemorrhage
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
stomatitis
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
gastrointestinal hemorrhage
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
toothache
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
abdominal discomfort
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
faeces discoloured
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
haematochezia
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
wheezing
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
4.6%
3/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Gastrointestinal disorders
large intestine perforation
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
hernia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
pain
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
swelling face
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
influenza like illness
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
General disorders
mucosal inflammation
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
rhinorrhoea
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
dysphonia
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
4.6%
3/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
haemoptysis
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
pulmonary embolism
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
pulmonary hypertension
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
sleep apnoea syndrome
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Respiratory, thoracic and mediastinal disorders
snoring
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
ejection fraction decreased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
neutrophil count decreased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
blood potassium decreased
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
blood uric acid decreased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
blood uric acid increased
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
international normalised ratio increased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
protein total decreased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
troponin T increased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Investigations
troponin increased
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
hypocalcaemia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
6.2%
4/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
hyperuricaemia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
failure to thrive
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
hypoproteinaemia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Metabolism and nutrition disorders
hypouricaemia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Blood and lymphatic system disorders
leukocytosis
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Eye disorders
retinopathy
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
28.6%
2/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Eye disorders
subretinal fluid
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Eye disorders
visual impairment
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
30.8%
20/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Eye disorders
chorioretinopathy
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Eye disorders
retinal haemorrhage
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Eye disorders
detachment of retinal pigment epithelium
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Eye disorders
lacrimation increased
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Eye disorders
macular oedema
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Skin and subcutaneous tissue disorders
pruritus
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Skin and subcutaneous tissue disorders
hair colour changes
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Skin and subcutaneous tissue disorders
alopecia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
25.0%
1/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Skin and subcutaneous tissue disorders
palmer-plantar erythrodysaesthesia syndrome
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Nervous system disorders
neuropathy peripheral
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Nervous system disorders
hypoaesthesia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Nervous system disorders
taste disorder
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Nervous system disorders
dyskinesia
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Vascular disorders
flushing
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
4.6%
3/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
upper respiratory tract infection
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
oral candidiasis
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
rash pustular
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
bronchitis
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
onychomycosis
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
pyelonephritis
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Infections and infestations
sepsis
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Renal and urinary disorders
acute kidney injury
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
8.3%
1/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
3.1%
2/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Renal and urinary disorders
dysuria
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Renal and urinary disorders
nephropathy
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Cardiac disorders
right ventricular failure
|
12.5%
1/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Psychiatric disorders
anxiety
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
4.6%
3/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Psychiatric disorders
depression
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Injury, poisoning and procedural complications
gastrointestinal stoma complication
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Reproductive system and breast disorders
vaginal haemorrhage
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
cancer pain
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
1.5%
1/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
14.3%
1/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
malignant ascites
|
0.00%
0/8 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
16.7%
1/6 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/12 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/65 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/7 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
0.00%
0/4 • AEs were collected from the start of intervention through 30 days post last day of study drug taken. Participants were monitored/assessed for adverse events for a maximum of 17 months which includes a maximum duration of 16 months on treatment.
Summary of serious treatment emergent adverse events in participants who received \> / = one dose of RMC-4630 and/or cobimetinib or in all participants who received \> / = one dose of RMC-4630 and/or osimertinib.
|
Additional Information
Vice-President Clinical Operations
Revolution Medicines
Phone: 650-779-2300
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place